1234365-97-9
1234365-97-9 structure
- Name: Tenapanor hydrochloride
- Chemical Name: tenapanor hydrochloride
- CAS Number: 1234365-97-9
- Molecular Formula: C50H68Cl6N8O10S2
- Molecular Weight: 1217.970
- Catalog: Signaling Pathways Membrane Transporter/Ion Channel Sodium Channel
- Create Date: 2018-06-05 21:01:38
- Modify Date: 2024-01-02 10:36:08
-
Tenapanor (AZD1722) hydrochloride is a potent and orally active sodium/hydrogen exchanger isoform 3 (NHE3) inhibitor. Tenapanor hydrochloride reduces intestinal phosphate absorption predominantly through reduction of passive paracellular phosphate flux. Tenapanor hydrochloride has the potential for the research of hyperphosphatemia[1][2].
| Name | tenapanor hydrochloride |
|---|---|
| Synonyms |
tenapanor HCl
N,N'-(10,17-Dioxo-3,6,21,24-tetraoxa-9,11,16,18-tetraazahexacosane-1,26-diyl)bis{3-[(4S)-6,8-dichloro-2-methyl-1,2,3,4-tetrahydro-4-isoquinolinyl]benzenesulfonamide} dihydrochloride tenapanor hydrochloride 50605O2ZNS RDX5791 AZD1722 hydrochloride 1,1'-(butane-1,4-diyl)bis{3-[2-(2-{2-[({3-[(4S)-6,8-dichloro-2-methyl-1,2,3,4-tetrahydroisoquinolin-4-yl]phenyl}sulfonyl)amino]ethoxy}ethoxy)ethyl]urea} dihydrochloride Benzenesulfonamide, N,N'-(10,17-dioxo-3,6,21,24-tetraoxa-9,11,16,18-tetraazahexacosane-1,26-diyl)bis[3-[(4S)-6,8-dichloro-1,2,3,4-tetrahydro-2-methyl-4-isoquinolinyl]-, hydrochloride (1:2) |
| Description | Tenapanor (AZD1722) hydrochloride is a potent and orally active sodium/hydrogen exchanger isoform 3 (NHE3) inhibitor. Tenapanor hydrochloride reduces intestinal phosphate absorption predominantly through reduction of passive paracellular phosphate flux. Tenapanor hydrochloride has the potential for the research of hyperphosphatemia[1][2]. |
|---|---|
| Related Catalog | |
| In Vivo | Tenapanor hydrochloride (0.15, 0.5 mg/kg; p.o.) reduces passive paracellular phosphate absorption in rats[1]. Tenapanor hydrochloride (0.15 mg/kg; p.o.; twice-daily for 11 consecutive days) increases the reduction in urinary phosphorus excretion in rats[2]. Animal Model: Rats (intestinal loop model)[1] Dosage: 0.15, 0.5 mg/kg Administration: P.o. Result: Reduced passive paracellular phosphate absorption by reduced urinary phosphate and sodium excretion after the high-phosphate meal and increased sodium and phosphate delivery to the cecum. Animal Model: 8 weeks, 250 g male Sprague–Dawley rats[2] Dosage: 0.15 mg/kg in combination with sevelamer (0%, 0.75%, 1.5%, and 3% (wt/wt)) Administration: Oral gavage; twice-daily for 11 consecutive days Result: Significantly augmented the reduction in urinary phosphorus excretion. |
| References |
| Molecular Formula | C50H68Cl6N8O10S2 |
|---|---|
| Molecular Weight | 1217.970 |
| Exact Mass | 1214.263062 |